La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Adicet Bio Gestion

Gestion contrôle des critères 2/4

Le PDG Adicet Bio's est Chen Schor, nommé en Sep2020, a un mandat de 4.08 ans. La rémunération annuelle totale est $ 5.97M, composée du salaire de 10.1% et des bonus 89.9%, y compris les actions et options de la société. détient directement 0.16% des actions de la société, d'une valeur de $ 194.25K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4 ans et 3.4 ans.

Informations clés

Chen Schor

Directeur général

US$6.0m

Rémunération totale

Pourcentage du salaire du PDG	10.1%
Durée du mandat du directeur général	4.1yrs
Propriété du PDG	0.2%
Durée moyenne d'occupation des postes de direction	4yrs
Durée moyenne du mandat des membres du conseil d'administration	3.4yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Chen Schor a-t-elle évolué par rapport aux bénéfices de Adicet Bio?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	-US$137m
Mar 31 2024	n/a	n/a	-US$140m
Dec 31 2023	n/a	n/a	-US$143m
Sep 30 2023	n/a	n/a	-US$143m
Jun 30 2023	n/a	n/a	-US$115m
Mar 31 2023	n/a	n/a	-US$105m
Dec 31 2022	US$4m	US$562k	-US$70m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$48m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$10m	US$536k	-US$62m
Sep 30 2021	n/a	n/a	-US$55m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$54m
Dec 31 2020	US$11m	US$499k	-US$37m

Rémunération vs marché: La rémunération totale de Chen ($USD 5.97M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 369.30K ).

Rémunération et revenus: La rémunération de Chen a augmenté alors que l'entreprise n'est pas rentable.

PDG

Chen Schor (52 yo)

4.1yrs

Titularisation

US$5,973,807

Compensation

Mr. Chen Schor, MBA, BA, CPA, serves as Chair of Carbon Biosciences, Inc. He has been the Chief Executive Officer, President & Director at Adicet Bio, Inc since September 15, 2020. He was a Co-Founder of r...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Chen Schor	CEO, President & Director	4.1yrs	US$5.97m	0.16% $ 195.6k
Aya Jakobovits	Founder & Independent Director	no data	US$240.29k	1.04% $ 1.2m
Brian Harvey	Chief Financial Officer	4.1yrs	US$2.13m	0.068% $ 81.3k
Donald Healey	Chief Technology Officer	4yrs	US$2.09m	0.043% $ 51.1k
Blake Aftab	Senior VP & Chief Scientific Officer	3.5yrs	US$2.48m	0.031% $ 36.8k
Amy Locke	Chief Human Resource Officer	2.8yrs	pas de données	pas de données
Francesco Galimi	Chief Medical Officer & Senior VP	4.1yrs	US$1.99m	0.092% $ 109.5k
Nancy Boman	Senior VP & Chief Regulatory Officer	1.9yrs	pas de données	pas de données

4.0yrs

Durée moyenne de l'emploi

59yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 0HX7 est considérée comme expérimentée (ancienneté moyenne 3.8 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Chen Schor	CEO, President & Director	4.1yrs	US$5.97m	0.16% $ 195.6k
Aya Jakobovits	Founder & Independent Director	4.1yrs	US$240.29k	1.04% $ 1.2m
Carl Gordon	Independent Chairman	4.1yrs	US$275.29k	0.0072% $ 8.6k
Steve Dubin	Independent Director	4.1yrs	US$254.29k	0.013% $ 15.8k
Andrew Sinclair	Independent Director	3.6yrs	US$255.29k	0.0072% $ 8.6k
Jeffrey Chodakewitz	Independent Director	4.1yrs	US$240.29k	0.0072% $ 8.6k
Marco Davila	Member of Scientific Advisory Board	3.3yrs	pas de données	pas de données
Lloyd Klickstein	Director	less than a year	US$2.90m	0.12% $ 148.9k
Michael Kalos	Member of Scientific Advisory Board	3.3yrs	pas de données	pas de données
Saul Priceman	Member of Scientific Advisory Board	3.3yrs	pas de données	pas de données
Constantine Mitsiades	Member of Scientific Advisory Board	3.3yrs	pas de données	pas de données
Alice Bertaina	Member of Scientific Advisory Board	3.3yrs	pas de données	pas de données

3.4yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de 0HX7 sont considérés comme expérimentés (ancienneté moyenne 3.5 ans).

Adicet Bio Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Adicet Bio, Inc Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome

Adicet Bio, Inc. Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases

Adicet Bio, Inc Announces ADI-001 Clinical Biomarker Data from the Phase 1 Glean Trial Which Further Reinforces the Potential of ADI-001 as Best-In-Class Allogeneic Cell Therapy for Autoimmune Diseases

Adicet Bio, Inc Announces Strategic Prioritization to Focus ADI-001 Development Resources on Autoimmune Indications

Adicet Bio, Inc. Announces Resignation of Michael Kauffman from the Board and Nominating and Corporate Governance Committee

Adicet Bio, Inc. Announces the Appointment of Lloyd Klickstein to its Board of Directors

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 2500 Value Index

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio, Inc., Annual General Meeting, Jun 05, 2024

Adicet Bio, Inc. Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the ASGCT 27th Annual Meeting

Adicet Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Adicet Bio, Inc. has completed a Follow-on Equity Offering in the amount of $85.199155 million.

Adicet Bio, Inc. Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study At the 65Th American Society of Hematology Annual Meeting

New minor risk - Market cap size

Adicet Bio, Inc. Announces Appointment of Katie Peng to the Board of Directors

New minor risk - Market cap size

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio, Inc. Presents Positive Preclinical Data on ADI-270 At the American Society of Gene and Cell Therapy (ASGCT) 26Th Annual Meeting

Full year 2022 earnings released: US$1.70 loss per share (vs US$2.00 loss in FY 2021)

High number of new and inexperienced directors

High number of new and inexperienced directors

Adicet Bio, Inc. Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Adicet Bio Inc. Appoints Nancy Boman, as Senior Vice President and Chief Regulatory Officer

High number of new and inexperienced directors

Adicet Bio, Inc. Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

High number of new and inexperienced directors

Second quarter 2022 earnings released: US$0.56 loss per share (vs US$0.34 loss in 2Q 2021)

Adicet Bio, Inc. Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc. Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)

First quarter 2022 earnings released: EPS: US$0.12 (vs US$0.82 loss in 1Q 2021)

Adicet Bio, Inc. Presents Preclinical Data at ISCT Annual Meeting Highlighting Potential Advantages of Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta Car T Cell Therapy Targeting CD20 for B Cell Malignancies

High number of new and inexperienced directors

Adicet Bio, Inc. Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology Annual Meeting

Adicet Bio, Inc., Annual General Meeting, Jun 02, 2022

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

High number of new and inexperienced directors

Adicet Bio Announces Positive Interim Clinical Data from First-Ever Allogeneic, Off-The-Shelf, Gamma Delta Car T Investigational Cell Therapy

Third quarter 2021 earnings released: US$0.44 loss per share (vs US$2.84 loss in 3Q 2020)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.48 loss in 2Q 2020)

Adicet Bio, Inc.(NasdaqGM:ACET) dropped from Russell 3000E Growth Index

Senior VP, Chief Scientific & Operating Officer Stewart Abbot has left the company

Adicet Bio, Inc., Annual General Meeting, Apr 27, 2021

Revenue beats expectations

Full year 2020 earnings released: US$5.01 loss per share (vs US$1.63 loss in FY 2019)

Adicet Bio, Inc. Announces Initiation of its First-In-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma

Adicet Bio, Inc. Announces Board Changes

Director has left the company

Adicet Bio, Inc. Announces Resignation of Lloyd Klickstein as Chief Innovation Officer

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen